glp-1 agonist. GLP-1R and Diabetes GLP-1 receptor agonists for individualized

Patoulias D, Michailidis T

This review summarizes current evidence on the efficacy and safety of available anti-obesity medications in children and adolescents, offering practical, age-based strategies to guide the appropriate clinical use of these medications as part of a comprehensive obesity-management plan

Weight change for pediatric completers in a national weight loss program

While short-acting versions like daily injections may better control postprandial glucose levels, they have largely been replaced by long-acting alternatives such as semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), which only require weekly injections

Clinical Applications Type 2 Diabetes Management Glucagon-like peptide-1 (GLP-1) agonists have emerged as a crucial class of medications for managing type 2 diabetes, a chronic condition characterized by insulin resistance and impaired glucose regulation